• Global drug delivery innovator Lexaria Bioscience is researching the ability of its patented DehydraTECH(TM) technology to improve the performance of a number of prescription drugs 
• Lexaria is a world leader in the investigation of a DehydraTECH-processed cannabidiol (“CBD”) to potentially treat high blood pressure (hypertension), and study outcomes thus far have rendered positive results on effectiveness and patient tolerance
• The company is building a scorecard of data to support its planned FDA application for formal, registered clinical testing under the Investigational New Drug (“IND”) process
• Lexaria recently completed all data analyses of its HYPER-H21-3 study examining DehydraTECH-CBD’s ability to reduce pulmonary artery systolic pressure, and launched HYPER-H21-4 to gather a variety of data points related to DehydraTECH-CBD’s use over a more extensive period of time

High blood pressure has long been labeled “the silent killer” because of its propensity to lead to incapacitating or prematurely deadly strokes, heart attacks and other serious disease indications without necessarily foreshadowing pain or great discomfort. According to the World Health Organization (“WHO”), an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension but only about 1 in 5 (21 percent) people with the condition have it under control with medical treatment (https://ibn.fm/uMZNh).

During the past decade within the United States, about 49 percent of the population reported taking at least one prescription medication in the past 30 days in data sampling collected by the National Center for Health Statistics of the Centers for Disease Control and Prevention at selected times, while 24 percent of the individuals took three or more prescriptions and 13 percent took five or more (https://ibn.fm/apjBj).

The data showed a marked increase over those persons sampled during the late 1980s to mid-1990s, particularly where multiple medications were concerned. And yet, a recent news report states that as few as 50 percent of patients take their medications exactly as prescribed (https://ibn.fm/ggwCv).

Global drug delivery innovator Lexaria Bioscience (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in their approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many of the obstacles that may hinder their proper use by patients. 

The company’s patented DehydraTECH(TM) technology combines an active pharmaceutical ingredient (“API”) with a fatty acid oil and performing a patented dehydration synthesis process before ingestion The Company has demonstrated significant improvements of absorption into bloodstream and even into brain tissue, in as little as minutes after ingestion.

One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (“FDA”) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (“CBD”) for the treatment of hypertension under the Investigational New Drug (“IND”) process.

Lexaria recently announced the launch of its HYPER-H21-4 randomized, double blinded, placebo-controlled, cross-over study of DehydraTECH-CBD in relation to  hypertension, with the potential for enhancing Lexaria’s ability to treat cardiovascular and other disease states beyond hypertension that are related to increased arterial stiffness (https://ibn.fm/F1N9A).

Lexaria has already completed other human studies. Last year, studies HYPER-H21-1 (https://ibn.fm/30edj) and HYPER-H21-2 (https://ibn.fm/RGDrr) provided evidence that DehydraTECH-CBD successfully reduced blood pressure in similarly hypertensive human volunteers, and Lexaria announced earlier this month that it had completed all data analyses of its HYPER-H21-3 study with positive safety and efficacy findings (https://ibn.fm/HS9sV).

HYPER-H21-3 used a placebo-controlled and double-blinded design with 16 volunteers, safely simulating hypoxia conditions (reduced oxygen availability) to induce lung artery constriction, or pulmonary hypertension, to analyze the ability of DehydraTECH-CBD to reduce pulmonary artery systolic pressure. 

HYPER-H21-4 will include 60 people and will be the most comprehensive study Lexaria has conducted to date. Dosing in more than half the volunteers has already begun and all treatment visits are expected to be finished by early July. 

The volunteers are between the ages of 40 and 70 with documented or measured elevated blood pressure, mild hypertension or moderate (stage 2) hypertension. The participants will use an escalating dose of DehydraTECH-CBD every day for a 5-week duration, establishing data for DehydraTECH-CBD’s extended use over time and providing secondary data outcomes that may ultimately lead to additional applications for DehydraTECH-CBD, according to the company. 

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]